Skip to main content
LXEO
NASDAQ Life Sciences

LX2006 Shows Sustained Neurologic Benefit Versus Natural-History Control

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$3.14
Mkt Cap
$257.757M
52W Low
$2.55
52W High
$10.99
52W Position info
23% above low
Off High info
71% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

LXEO sits 23% above its 52-week low of $2.55.

Summary

Lexeo reported interim phase I/II data for LX2006 showing sustained or deepening improvements in cardiac and neurologic measures, including a statistically significant mean mFARS improvement versus a propensity-matched natural-history control. A controlled neurologic outcome is the key addition here — prior LX2006 updates centered on cardiac benefit, and this extends the efficacy case into the Friedreich's ataxia neurologic endpoint. The release gives no effect size, no comparison-period figures, and no quantified durability, so the magnitude is still unknown. This comes after the August 12 8-K disclosing SUNRISE-FA 2 initiation and the September Mantle Therapeutics acquisition that added a multimodal FA pipeline. Full data through 36 months is slated for presentation at ICAR in November — that readout is where effect size and durability get settled.

At the time of this announcement, LXEO was trading at $3.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $257.8M. The 52-week trading range was $2.55 to $10.99. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

LXEO - Latest Insights

LXEO
Nov 16, 2026, 7:05 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.20
Real-time Price: $2.90 info
Change: -$0.300 (-9%) info
Market Cap: $234.706M info
LXEO
Nov 16, 2026, 7:02 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.99
Real-time Price: $2.90 info
Change: -$0.090 (-3%) info
Market Cap: $234.706M info
LXEO
Nov 16, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.85
Real-time Price: $2.90 info
Change: +$0.050 (+2%) info
Market Cap: $234.706M info
LXEO
Sep 22, 2026, 7:08 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.84
Real-time Price: $2.90 info
Change: -$0.944 (-25%) info
Market Cap: $234.706M info
LXEO
Sep 22, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $4.18
Real-time Price: $2.90 info
Change: -$1.28 (-31%) info
Market Cap: $234.706M info